Neurogene Analyst Price Targets - Benzinga

Neurogene Inc

NGNENASDAQ

Trade with Public

Trade with Public

$37.61

-0.75-1.96%

At close: Sep 2, 5:00 PM EST

$37.61

-0.75-1.96%

Pre-Market: 8:52 AM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Neurogene Analyst Price Targets

Wall Street analyst price targets and consensus rating for Neurogene (NGNE).

Price Target Range — 10 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$60Upside to Avg. PT+58.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 12, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$180→$166
Aug 12, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$69→$81
Aug 12, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$70→$65
Jun 9, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$70
Apr 6, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$200→$180
Feb 27, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$200
Jan 26, 2026	LifeSci Capital	Patrick Dolezal	Initiate	Outperform	$50
Jan 13, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$70
Nov 13, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$65→$70
Oct 31, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$45→$65
Oct 9, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$45
Jun 17, 2025	Craig-Hallum	Albert Lowe	Initiate	Buy	$50
Jun 12, 2025	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$22→$26
May 20, 2025	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$16→$22
May 16, 2025	Baird	Joel Beatty	Downgrade	Outperform→Neutral	$38→$24
May 13, 2025	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Buy	$50→$45
Apr 14, 2025	BMO Capital	Keith Tapper	PT Cut	Outperform	$45→$16
Mar 25, 2025	Baird	Joel Beatty	PT Cut	Outperform	$46→$36
Mar 25, 2025	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Buy	$55→$50
Nov 25, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$55

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166

Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $180 to $166.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81

Guggenheim analyst Debjit Chattopadhyay maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target from $69 to $81.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $70 to $65.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $70 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $70 price target.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $180

Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $200 to $180.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Neurogene with Buy Rating, Announces Price Target of $200

Canaccord Genuity analyst Whitney Ijem initiates coverage on Neurogene (NASDAQ:NGNE) with a Buy rating and announces Price Target of $200.

Benzinga Newsdesk